Fibromyalgia, Thyroid Dysfunction and Treatment Modalities
Michael Friedman
PDF
HTML

Keywords

Fibromyalgia
Thyroid antibodies
Thyroid dysfunction
Thyroid hormones
PDF
HTML

Abstract

Fibromyalgia is a debilitating condition presenting with symptoms of chronic muscular pain, fatigue, insomnia and cognitive dysfunction among other symptoms, which lead to a diminished quality of life. Although the exact pathogenesis and underlying mechanisms which lead to clinical manifestation are unknown, there is a growing line of evidence suggesting an association between fibromyalgia and thyroid dysfunction. Numerous studies have reported that patients with fibromyalgia have a high incidence of hypothyroidism. Further, thyroid autoimmunity has also been associated with fibromyalgia symptom severity. Circulating thyroid hormones do not provide an accurate status of thyroid function in patients with fibromyalgia, rather intracellular thyroid hormone levels are more relevant. Low levels of intracellular hormones may result from mitochondrial dysfunction as active transport of hormones across cellular membranes is required. It is well known that mitochondrial dysfunction is associated with fibromyalgia. In order to correct thyroid dysfunction and manage symptoms presenting in fibromyalgia patients, a multi-disciplinary approach should be taken incorporating dietary supplements, nutraceuticals, dietary changes and complementary alternative therapies.

PDF
HTML

References

McDonald M, DiBonaventura M, Ullman S. Musculoskeletal pain in the workforce: the effects of back, arthritis, and fibromyalgia pain on quality of life and work productivity. J Occup Environ Med. 2011; 53:765–70.
Lindell L, Bergman S, Petersson IF, Jacobsson LT, Herrstrom P. Prevalence of fibromyalgia and chronic widespread pain. Scand J Prim Health Care. 2000; 18:149–53.
Wolfe F, Ross K, Anderson J, Russell IJ, Hebert L. The prevalence and characteristics of fibromyalgia in the general population. Arthritis Rheum. 1995; 38:19–28.
Sanchez RJ, Uribe C, Li H, et al. Longitudinal evaluation of health care utilization and costs during the first three years after a new diagnosis of fibromyalgia. Curr Med Res Opin. 2011; 27:663–71.
Wolfe F, Anderson J, Harkness D, et al. A prospective, longitudinal, multicenter study of service utilization and costs in fibromyalgia. Arthritis Rheum. 1997; 40:1560–70.
Sacks JJ, Luo YH, Helmick CG. Prevalence of specific types of arthritis and other rheumatic conditions in the ambulatory health care system in the United States, 2001–2005. Arthritis Care Res (Hoboken). 2010; 62:460–4.
Bernatsy S, Dobkin PL, DeCivita M, Pernod JR. Co-morbidity and physician use in fibromyalgia. Swiss Med Wkly. 2005; 135:76–81.
Schneider MJ, Brady DM, Perle SM. Commentary: differential diagnosis of fibromyalgia syndrome: proposal of a model and algorithm for patients presenting with the primary symptom of chronic widespread pain. J Manipulative Physiol Ther. 2006; 29:493–501.
Wolfe F, Clauw DJ, Fitzcharles MA, et al. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity. Arthritis Care Res (Hoboken). 2010; 62:600–10.
Crofford LJ. The hypothalamic-pituitary-adrenal axis in the pathogenesis of rheumatic diseases. Endocrinol Metab Clin North Am. 2002; 31:1–13.
Clauw DJ, Arnold LM, McCarberg BH. The science of fibromyalgia. Mayo Clin Proc. 2011; 86:907–11.
Arnold LM. The pathophysiology, diagnosis and treatment of fibromyalgia. Psychiatr Clin North Am. 2010; 33:375–408.
Buskila D. Fibromyalgia, chronic fatigue syndrome, and myofascial pain syndrome. Curr Opin Rheumatol. 2001; 13:117–27.
DeLeo JA, Yezierski RP. The role of neuroinflammation and neuroimmune activation in persistent pain. Pain. 2001; 90:1–6.
Bazzichi L, Rossi A, Giuliano T, et al. Association between thyroid autoimmunity and fibromyalgic disease severity. Clin Rheumatol. 2007; 26:2115–20.
Pamuk ON, Cakir N. The frequency of thyroid antibodies in fibromyalgia patients and their relationship with symptoms. Clin Rheumatol. 2007; 26:55–9.
Toruner F. Association of fibromyalgia with Hashimoto’s thyroiditis. European Thyroid Association Annual Meeting, Istanbul, Turkey, 2004.
Lowe JC, Yellin J. Inadequate thyroid hormone regulation as the main mechanism of fibromyaglia: a review of the evidence. Thyroid Sci. 2008; 3:R1–14.
Suk JH, Lee JH, Kim JM. Association between thyroid autoimmunity and fibromyalgia. Exp Clin Endocrinol Diabetes. 2012; 120:401–4.
Ribeiro LS, Proietti FA. Interrelations between fibromyalgia, thyroid autoantibodies, and depression. J Rheumatol. 2004; 31:2036–40.
Bazzichi L, Rossi A, Zirafa C, et al. Thyroid autoimmunity may represent a predisposition for the development of fibromyalgia? Rheumatol Int. 2012; 32:335–41.
Ruchala M, Kosowicz J, Baumann-Antczak A, Skiba A, Zamyslowska H, Sowinski J. The prevalence of autoantibodies to: myosin, troponin, tropomyosin and myoglobin in patients with circulating triiodothyronine and thyroxine autoantibodies (THAA). Neuro Endocrinol Lett. 2007; 28:259–66.
Lowe JC, Yellin J, Honeyman-Lowe G. Female fibromyalgia patients: lower resting metabolic rates than matched healthy controls. Med Sci Monit. 2006; 12:CR282–9.
Henry JL, Sessle BJ, Lucier GE, Hu JW. Effects of substance P on nociceptive and non-nociceptive trigeminal brain stem neurons. Pain. 1980; 8:33–45.
Malmberg AB, Yaksh TL. Hyperalgesia mediated by spinal glutamate or substance P receptor blocked by spinal cyclooxygenase inhibition.Science. 1992; 257:1276–9.
Savard P, Blanchard LM, Merand Y, Bedard P, Dussault JH, Dupont A. Influences of both thyroid and bovine growth hormones on substance P, thyrotropin-releasing hormone, serotonin and 5-hydroxyindoleacetic acid contents in the lumbar spinal cord of developing rats. Brain Res. 1984; 315:105–10.
Lowe JC. Thyroid status of 38 fibromyalgia patients: implications for the etiology of fibromyalgia. Clin Bull Myofascial Ther. 1997; 2:36–41.
Lowe JC. T3-induced recovery from fibromyalgia by a hypothyroid patient resistant to T4 and desiccated thyroid. J Myofascial Ther. 1995; 1:26–31.
Lowe JC, Garrison RL, Reichman AJ, Yellin J, Thompson M, Kaufman D. Effectiveness and safety of T3 (triiodothyronine) theraphy for euthyroid fibromyalgia: a double-blind placebo-controlled response-driven crossover study. Clin Bull Myofascial Ther. 1997; 2:71–88.
Lowe JC, Eichelberger J, Manso G, Peterson K. Improvement in euthyroid fibromyalgia patients treated with T3 triiodothyronine. J Myofascial Ther. 1994; 1:16–27.
Everts ME, de JM, Lim CF, et al. Different regulation of thyroid hormone transport in liver and pituitary: its possible role in the maintenance of low T3 production during nonthyroidal illness and fasting in man. Thyroid. 1996; 6:359–68.
Wassen FW, Moerings EP, van TH, Hennemann G, Everts ME. Thyroid hormone uptake in cultured rat anterior pituitary cells: effects of energy status and bilirubin. J Endocrinol. 2000; 165:599–606.
Schimmel M, Utiger RD. Thyroidal and peripheral production of thyroid hormones. Review of recent findings and their clinical implications. Ann Intern Med. 1977; 87:760–8.
Sarne DH, Refetoff S. Measurement of thyroxine uptake from serum by cultured human hepatocytes as an index of thyroid status: reduced thyroxine uptake from serum of patients with nonthyroidal illness. J Clin Endocrinol Metab. 1985; 61:1046–52.
Banos C, Tako J, Salamon F, Gyorgyi S, Czikkely R. Effect of ACTH-stimulated glucocorticoid hypersecretion on the serum concentrations of thyroxine-binding globulin, thyroxine, triiodothyronine, reverse triiodothyronine and on the TSH-response to TRH. Acta Med Acad Sci Hung. 1979; 36:381–94.
Hackney AC, Feith S, Pozos R, Seale J. Effects of high altitude and cold exposure on resting thyroid hormone concentrations. Aviat Space Environ Med. 1995; 66:325–9.
Heyma P, Larkins RG. Glucocorticoids decrease in conversion of thyroxine into 3, 5, 3′-tri-iodothyronine by isolated rat renal tubules. Clin Sci (Lond). 1982; 62:215–20.
Dommerholt J, Huijbregts P. Myofascial Trigger Points: Pathophysiology and Evidence-Informed Diagnosis and Management. Burlington, MA: Jones & Bartlett Publishers, 2011.
Gerwin RD. A review of myofascial pain and fibromyalgia—factors that promote their persistence. Acupunct Med. 2005; 23:121–34.
van den Beld AW, Visser TJ, Feelders RA, Grobbee DE, Lamberts SW. Thyroid hormone concentrations, disease, physical function, and mortality in elderly men. J Clin Endocrinol Metab. 2005; 90:6403–9.
Hennemann G, Docter R, Friesema EC, de JM, Krenning EP, Visser TJ. Plasma membrane transport of thyroid hormones and its role in thyroid hormone metabolism and bioavailability. Endocr Rev. 2001; 22:451–76.
Hennemann G, Vos RA, de JM, Krenning EP, Docter R. Decreased peripheral 3,5,3′-triiodothyronine (T3) production from thyroxine (T4): a syndrome of impaired thyroid hormone activation due to transport inhibition of T4- into T3-producing tissues. J Clin Endocrinol Metab. 1993; 77:1431–5.
Krenning E, Docter R, Bernard B, Visser T, Hennemann G. Regulation of the active transport of 3,3′,5-triiodothyronine (T3) into primary cultured rat hepatocytes by ATP. FEBS Lett. 1980; 119:279–82.
Szendroedi J, Schmid AI, Meyerspeer M, et al. Impaired mitochondrial function and insulin resistance of skeletal muscle in mitochondrial diabetes. Diabetes Care. 2009; 32:677–9.
Abdul-Ghani MA, Jani R, Chavez A, Molina-Carrion M, Tripathy D, Defronzo RA. Mitochondrial reactive oxygen species generation in obese non-diabetic and type 2 diabetic participants. Diabetologia. 2009; 52:574–82.
Corral-Debrinski M, Shoffner JM, Lott MT, Wallace DC. Association of mitochondrial DNA damage with aging and coronary atherosclerotic heart disease. Mutat Res. 1992; 275:169–80.
Lim CF, Docter R, Visser TJ, et al. Inhibition of thyroxine transport into cultured rat hepatocytes by serum of nonuremic critically ill patients: effects of bilirubin and nonesterified fatty acids. J Clin Endocrinol Metab. 1993; 76:1165–72.
de JM, Docter R, Van Der Hoek HJ, Vos RA, Krenning EP, Hennemann G. Transport of 3,5,3′-triiodothyronine into the perfused rat liver and subsequent metabolism are inhibited by fasting. Endocrinology. 1992; 131:463–70.
Pieczenik SR, Neustadt J. Mitochondrial dysfunction and molecular pathways of disease. Exp Mol Pathol. 2007; 83:84–92.
Modica-Napolitano JS, Renshaw PF. Ethanolamine and phosphoethanolamine inhibit mitochondrial function in vitro: implications for mitochondrial dysfunction hypothesis in depression and bipolar disorder. Biol Psychiatry. 2004; 55:273–7.
Gardner A, Boles RG. Mitochondrial energy depletion in depression with somatization. Psychother Psychosom. 2008; 77:127–9.
Burroughs S, French D. Depression and anxiety: role of mitochondria. Current Anesthesia Crit Care. 2007; 18:34–41.
Fulle S, Mecocci P, Fano G, et al. Specific oxidative alterations in vastus lateralis muscle of patients with the diagnosis of chronic fatigue syndrome. Free Radic Biol Med. 2000; 29:1252–9.
Buist R. Elevated xenobiotics, lactate and pyruvate in C.F.S. patients. J Orthomolec Med. 1989; 4:170–2.
Kaptein EM. Thyroid hormone metabolism and thyroid diseases in chronic renal failure. Endocr Rev. 1996; 17:45–63.
Lowe JC, Honeyman G, Yellin J. Lower resting metabolic rate and basal body temperature of fibromyalgia patients compared to matched healthy controls. Thyroid Sci. 2006; 1:1–18.
Wikstrom L, Johansson C, Salto C, et al. Abnormal heart rate and body temperature in mice lacking thyroid hormone receptor alpha 1. EMBO J. 1998; 17:455–61.
Safer JD, O’Connor MG, Colan SD, Srinivasan S, Tollin SR, Wondisford FE. The thyroid hormone receptor-beta gene mutation R383H is associated with isolated central resistance to thyroid hormone. J Clin Endocrinol Metab. 1999; 84:3099–109.
Moriyama K, Tagami T, Akamizu T, et al. Thyroid hormone action is disrupted by bisphenol A as an antagonist. J Clin Endocrinol Metab. 2002; 87:5185–90.
Vandenberg LN, Maffini MV, Sonnenschein C, Rubin BS, Soto AM. Bisphenol-A and the great divide: a review of controversies in the field of endocrine disruption. Endocr Rev. 2009; 30:75–95.
Yan S, Chen Y, Dong M, Song W, Belcher SM, Wang HS. Bisphenol A and 17beta-estradiol promote arrhythmia in the female heart via alteration of calcium handling. PLoS One. 2011; 6:e25455.
Heimeier RA, Das B, Buchholz DR, Shi YB. The xenoestrogen bisphenol A inhibits postembryonic vertebrate development by antagonizing gene regulation by thyroid hormone. Endocrinology. 2009; 150:2964–73.
Zoeller RT, Bansal R, Parris C. Bisphenol-A, an environmental contaminant that acts as a thyroid hormone receptor antagonist in vitro, increases serum thyroxine, and alters RC3/neurogranin expression in the developing rat brain. Endocrinology. 2005; 146:607–12.
McKinney JD, Waller CL. Polychlorinated biphenyls as hormonally active structural analogues. Environ Health Perspect. 1994; 102:290–7.
Schantz SL, Widholm JJ, Rice DC. Effects of PCB exposure on neuropsychological function in children. Environ Health Perspect. 2003; 111:357–576.
Boucher O, Muckle G, Bastien CH. Prenatal exposure to polychlorinated biphenyls: a neuropsychologic analysis. Environ Health Perspect. 2009; 117:7–16.
Chevrier J, Harley KG, Bradman A, Gharbi M, Sjodin A, Eskenazi B. Polybrominated diphenyl ether (PBDE) flame retardants and thyroid hormone during pregnancy. Environ Health Perspect. 2010; 118:1444–9.
Lin SM, Chen FA, Huang YF, et al. Negative associations between PBDE levels and thyroid hormones in cord blood. Int J Hyg Environ Health. 2011; 214:115–20.
Zorrilla LM, Gibson EK, Jeffay SC, et al. The effects of triclosan on puberty and thyroid hormones in male Wistar rats. Toxicol Sci. 2009; 107:56–64.
Calafat AM, Ye X, Wong LY, Reidy JA, Needham LL. Urinary concentrations of triclosan in the U.S. population: 2003–2004. Environ Health Perspect. 2008; 116:303–7.
Kunisue T, Fisher JW, Kannan K. Modulation of thyroid hormone concentrations in serum of rats coadministered with perchlorate and iodide-deficient diet. Arch Environ Contam Toxicol. 2011; 61:151–8.
Goldenberg DL, Burckhardt C, Crofford L. Management of fibromyalgia syndrome. J Am Med Assoc. 2004; 292:2388–95.
Wahner-Roedler DL, Elkin PL, Vincent A, et al. Use of complementary and alternative medical therapies by patients referred to a fibromyalgia treatment program at a tertiary care center. Mayo Clin Proc. 2005; 80:55–60.
Kelly G. Body temperature variability (Part 1): a review of the history of body temperature and its variability due to site selection, biological rhythms, fitness, and aging. Altern Med Rev. 2006; 11:278–93.
Friedman M, Miranda-Massari JR, Gonzalez MJ. Supraphysiological cyclic dosing of sustained release T3 in order to reset low basal body temperature. P R Health Sci J. 2006; 25:23–9.
Kurland GS, Hamolsky MW, Feedberg AS. Studies in non-myxedematous hypermetabolism: 1. The clinical syndrome an the effects of triidothyroinine, alone or combined with thyroxine. J Clin Endocrinol. 1955; 15:1354.
Lowe JC, Reichman A, Yellin J. The process of change with T3 therapy for euthyroid fibromyalgia: a double-blind, placebo-controlled crossover study. Clin Bull Myofascial Ther. 1997; 2:91–124.
Teitelbaum J, Bird B, Greenfield RM, Weiss A, Muenz L, Gould L. Effective treatment of chronic fatigue syndrome (CFIDS) & fibromyalgia (FMS) — A randomized, double-blind, placebo-controlled, intent to treat study. J Chronic Fatigue Syndr. 2000; 8:3–15.
Johannsen DL, Galgani JE, Johannsen NM, Zhang Z, Covington JD, Ravussin E. Effect of short-term thyroxine administration on energy metabolism and mitochondrial efficiency in humans. PLoS One. 2012; 7:e40837.
Lowe JC, Reichman AJ, Yellin J. A case-control study of metabolic therapy for fibromyalgia: long-term follow-up comparison of treated and untreated patients. Clin Bull Myofascial Ther. 1998; 3:65–79.
Escobar-Morreale HF, del Rey FE, Obregon MJ, de Escobar GM. Only the combined treatment with thyroxine and triiodothyronine ensures euthyroidism in all tissues of the thyroidectomized rat. Endocrinology. 1996; 137:2490–502.
Hanafusa J, Mune T, Tanahashi T, et al. Altered corticosteroid metabolism differentially affects pituitary corticotropin response. Am J Physiol Endocrinol Metab. 2002; 282:E466–73.
Frances D. Botanical approaches to hypothyroidism: avoiding supplemental thyroid hormone. Med Herbalism. 2002; 12:1–5.
Panda S, Kar A. Gugulu (Commiphora mukul) induces triiodothyronine production: possible involvement of lipid peroxidation. Life Sci. 1999; 65:L137–41.
Singh AK, Tripathi SN, Prasad GC. Response of commiphora mukul (guggulu) on melatonin induced hypothyroidism. Anc Sci Life. 1983; 3:85–90.
Johnson TL, Fahey JW. Black cohosh: coming full circle? J Ethnopharmacol. 2012; 141:775–9.
Mills SY, Jacoby RK, Chacksfield M, Willoughby M. Effect of a proprietary herbal medicine on the relief of chronic arthritic pain: a double-blind study. Br J Rheumatol. 1996; 35:874–8.
Soeken KL, Miller SA, Ernst E. Herbal medicines for the treatment of rheumatoid arthritis: a systematic review. Rheumatology (Oxford). 2003; 42:652–9.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY-NC-ND 4.0). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.